Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

Results from phase 2a trial in ALS patients were published in Muscle and Nerve.Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records.NfL was reduced by 27% for patients treated for at least two months.Unadjusted median survival for participants in the IPL344 group was 43.4 months compared with 19.1 months in the historical control group.IPL344 was safe and well-tolerated.View original content:https://www.prnewswire.co.uk/news-releases/immunity-pharma-presents-new-data-supporting-the-efficacy-of-ipl344-in-als-302421483.html

@ prnewswire.co.uk

Hol dir den Wissensvorsprung der Profis. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Trading-Empfehlungen – dreimal die Woche, direkt in dein Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr.
Jetzt anmelden.